Aspenbio Pharma (APPY) 1.94 $APPY
Haemonetics (HAE) Crumbles: Stock Falls 6.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:31AM CDT
Haemonetics (HAE) fell over 6% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.
Zimmer Holdings (ZMH) Soars: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:51AM CDT
Zimmer Holdings, Inc. (ZMH) was a big mover last session, as its shares rose nearly 12% on the day.
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
MacroGenics (MGNX) Jumps: Stock Up 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 8:39AM CDT
MacroGenics, Inc. was a big mover last session, as its shares rose nearly 8% on the day.
GW Pharmaceuticals plc (GWPH) Soars: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:51AM CDT
GW Pharmaceuticals plc was a big mover last session, as its shares rose nearly 14% on the day.
Weakness Seen in Unilife (UNIS): Stock Tumbles 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:49AM CDT
Unilife Corporation (UNIS) saw a big move last session,continuing the recent downtrend for URS, as the stock is now down around 34.50% in the past one-month time frame.
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Venaxis, Inc. Closes Public Offering of Common Shares
PR Newswire - Tue Apr 08, 3:01PM CDT
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any.
Nasdaq stocks posting largest volume increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Venaxis (APPY) Stock Is Down Today
at The Street - Thu Apr 03, 10:25AM CDT
Venaxis (APPY) fell on Thursday after the diagnostic company announced the pricing of its public offering of common stock. Venaxis is offering 8,335,000 shares at $2.40 a share for a total of $20 million. The offering includes a 30-day option for...
Stock to Watch: AspenBio Pharma Down 11.1% (APPY)
Comtex SmarTrend(R) - Thu Apr 03, 10:11AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.1% to $2.41 on 2.6x average daily volume. Thus far today, AspenBio Pharma has traded 2.0 million shares, vs. average volume of 759,000 shares per day. The stock has underperformed the Dow (-11.1% to the Dow's -0.1%) and underperformed the S&P 500 (-11.1% to the S&P's -0.1%) during today's trading.
Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares
PR Newswire - Thu Apr 03, 8:00AM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the pricing of an underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about April 8, 2014, subject to customary closing conditions.
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AspenBio Pharma Up 27.2%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Thu Mar 13, 10:16AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 27.2% to $3.45 on 17.9x average daily volume. AspenBio Pharma has traded 6.8 million shares thus far today, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (27.2% to the Dow's -0.2%) and outperformed the S&P 500 (27.2% to the S&P's -0.2%) during today's trading.
Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Thu Mar 13, 6:00AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
Haemonetics (HAE) Crumbles: Stock Falls 6.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:31AM CDT
Haemonetics (HAE) fell over 6% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.
Zimmer Holdings (ZMH) Soars: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:51AM CDT
Zimmer Holdings, Inc. (ZMH) was a big mover last session, as its shares rose nearly 12% on the day.
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:49AM CDT
Agios Pharmaceuticals, Inc. (AGIO) saw a big move last session, reversing the recent trend for AGIO as the stock is now up around 16.0% in the past one-month time frame.
MacroGenics (MGNX) Jumps: Stock Up 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 8:39AM CDT
MacroGenics, Inc. was a big mover last session, as its shares rose nearly 8% on the day.
GW Pharmaceuticals plc (GWPH) Soars: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:51AM CDT
GW Pharmaceuticals plc was a big mover last session, as its shares rose nearly 14% on the day.
Weakness Seen in Unilife (UNIS): Stock Tumbles 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:49AM CDT
Unilife Corporation (UNIS) saw a big move last session,continuing the recent downtrend for URS, as the stock is now down around 34.50% in the past one-month time frame.
Pre-Market Scans on Top Gainers -- Research on Athlon Energy, Venaxis, Desarrolladora Homex, and ImmunoGen
PR Newswire - Thu Apr 10, 12:30PM CDT
On Wednesday, April 09, 2014, the US markets saw a positive sentiment, as the NASDAQ Composite closed at 4,183.90, up 1.72%, the Dow Jones Industrial Average ended the session at 16,437.18, up 1.11%, and the S&P 500 edged 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Athlon Energy Inc. (NYSE: ATHL), Venaxis Inc. (NASDAQ: APPY), Desarrolladora Homex S.A.B. de C.V. (NYSE: HXM) and ImmunoGen Inc. (NASDAQ: IMGN). Free technical research on ATHL, APPY, HXM and IMGN can be downloaded upon signing up at:
Venaxis, Inc. Closes Public Offering of Common Shares
PR Newswire - Tue Apr 08, 3:01PM CDT
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any.
Nasdaq stocks posting largest volume increases
AP - Thu Apr 03, 5:24PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Venaxis (APPY) Stock Is Down Today
at The Street - Thu Apr 03, 10:25AM CDT
Venaxis (APPY) fell on Thursday after the diagnostic company announced the pricing of its public offering of common stock. Venaxis is offering 8,335,000 shares at $2.40 a share for a total of $20 million. The offering includes a 30-day option for...
Stock to Watch: AspenBio Pharma Down 11.1% (APPY)
Comtex SmarTrend(R) - Thu Apr 03, 10:11AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.1% to $2.41 on 2.6x average daily volume. Thus far today, AspenBio Pharma has traded 2.0 million shares, vs. average volume of 759,000 shares per day. The stock has underperformed the Dow (-11.1% to the Dow's -0.1%) and underperformed the S&P 500 (-11.1% to the S&P's -0.1%) during today's trading.
Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares
PR Newswire - Thu Apr 03, 8:00AM CDT
Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced the pricing of an underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about April 8, 2014, subject to customary closing conditions.
Venaxis Files for FDA Clearance of APPY1 Test
PR Newswire - Mon Mar 31, 6:30AM CDT
CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis(TM) has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AspenBio Pharma Up 27.2%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Thu Mar 13, 10:16AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 27.2% to $3.45 on 17.9x average daily volume. AspenBio Pharma has traded 6.8 million shares thus far today, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (27.2% to the Dow's -0.2%) and outperformed the S&P 500 (27.2% to the S&P's -0.2%) during today's trading.
Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Thu Mar 13, 6:00AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
